ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,765 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentSchlierenNeurimmune Subone AG
Neurimmune Subone AG Logo
Verified· 3 sourcesTrust Score
Summary

About the company

Neurimmune Subone AG is a biopharmaceutical company that translates human immune memory into antibody therapeutics. It develops monoclonal antibody candidates for indications including Alzheimer’s disease, amyotrophic lateral sclerosis, spinal cord injury, ATTR cardiomyopathy and type‑2 diabetes, applying its Reverse Translational Medicine™ (RTM™) technology platform and pursuing discovery, early clinical development and strategic partnerships.

AI-generated
Offering

Products & services

Industry:Research & Development
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.0/5

Neurimmune Subone AG

✓ Offered4
Antibody therapeutics
Antibody therapeutics for protein aggregation disorders, developed as fully human antibody candidates for selective binding to pathological protein forms and for sparing physiological target structures.
Amyloid depletion
Selective removal of misfolded or aggregated proteins using human antibodies to label pathological target structures and enable their immune-mediated clearance.
Reverse Translational Medicine™ (RTM™)
Research platform for deriving fully human therapeutic antibodies from genetic blueprints of immune cells from older people and for identifying selective, high-affinity candidates.
Pipeline of clinical and preclinical antibody candidates
Development of antibody candidates against ATTR cardiomyopathy, amyotrophic lateral sclerosis, spinal cord injury, AL amyloidosis and Alzheimer’s disease.
Trust & reputation

ranQ Trust Score of Neurimmune Subone AG: 4.0 out of 5.0

Trust Score4.0/ 5.0

High

x

Data basis 96% · As of October 2026

Neurimmune Subone AG scores 49.8 out of 100 points in the Reputation area of the ranQ Trust Score. This area carries 42% of the weighting.
x
CriterionValueWeight
  • Review quality: The average rating across all connected sources, smoothed against the industry mean. So 5.0 stars from three reviews do not outrank 4.7 from three hundred.68.224%
  • Review volume: The number of reviews across all sources. The scale is logarithmic: the first reviews count the most, and the maximum is reached at 50 reviews.17.610%
  • Review recency: The age of the most recent review. Two-year-old reviews deliberately sit in the middle, because that is normal for Swiss SMEs. Only after three years without a new voice does the value drop markedly.35.08%
Neurimmune Subone AG scores 85.5 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.100.012%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.55.07%
Neurimmune Subone AG scores 85.0 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).85.022%
Neurimmune Subone AG scores 100.0 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.100.04%
  • Media authority: No data point — the criterion is taken out of the weighting and does not lower the score.—4%
Qualifications+0.00

Neurimmune Subone AG reaches a ranQ Trust Score of 4.0 out of 5.0 — rated «High». The rating draws, among other things, on 5.0 out of 5 stars from 1 customer reviews. The data basis is 96%, so the score is backed by part of the criteria. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Reviews

Aggregated rating

Aggregated rating
5
of 5

Aggregated from 1 reviews across all connected sources

Sources
GGoogle51
★TrustpilotSoon
PProvenExpertSoon

Further sources are added continuously and factored into the ranQ Rating.

Knowledge

No knowledge articles yet

Once Neurimmune Subone AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Neurimmune Subone AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Neurimmune Subone AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Neurimmune Subone AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Wagistrasse 18
8952 Schlieren

At a glance

Legal form
Corporation
UID
CHE-113.902.651
Founded
2007 · 19 years
Last commercial register change
September 8, 2021
Employees
1 to 10
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    MP
    Molecular Partners AG
    Schlieren
    AT
    Axanton Technology GmbH
    Schlieren
    MA
    Mabylon AG
    Schlieren
    PA
    Philochem AG
    Otelfingen
    NT
    Numab Therapeutics AG
    Horgen
    EA
    evitria AG
    Fahrweid
    FM
    FELS Medical GmbH
    Glattpark (Opfikon)
    CR
    Charles River Laboratories Switzerland AG
    Hettlingen